Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

MYCN Amplified Relapse Following Resolution of MYCN Nonamplified 4S Neuroblastoma With Placental Involvement: A Case Report and Review of the Literature.

Langenberg-Ververgaert KPS, Renzi S, Chung CT, Shago M, Lo W, Davidson S, Villani A, Baruchel S, Irwin MS, Morgenstern DA.

J Pediatr Hematol Oncol. 2019 Jul;41(5):388-391. doi: 10.1097/MPH.0000000000001515.

PMID:
31094905
2.

An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome.

Wilbur C, Yea C, Licht C, Irwin MS, Yeh EA.

Pediatr Blood Cancer. 2019 Aug;66(8):e27776. doi: 10.1002/pbc.27776. Epub 2019 Apr 29.

PMID:
31033188
3.

Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).

Pinto N, Naranjo A, Hibbitts E, Kreissman SG, Granger MM, Irwin MS, Bagatell R, London WB, Greengard EG, Park JR, DuBois SG.

Eur J Cancer. 2019 May;112:66-79. doi: 10.1016/j.ejca.2019.02.003. Epub 2019 Apr 1.

PMID:
30947024
4.

Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System.

Naranjo A, Irwin MS, Hogarty MD, Cohn SL, Park JR, London WB.

JCO Clin Cancer Inform. 2018 Dec;2:1-15. doi: 10.1200/CCI.17.00140.

5.

Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.

Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon BPK, St-Germain J, Cook JD, Valencia-Sama I, Grant BMM, Herrera SG, Miao J, Raught B, Irwin MS, Lee JE, Yeh JJ, Zhang ZY, Tsao MS, Ikura M, Ohh M.

Nat Commun. 2019 Jan 15;10(1):224. doi: 10.1038/s41467-018-08115-8.

6.

The challenge of defining "ultra-high-risk" neuroblastoma.

Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, London WB, Irwin MS.

Pediatr Blood Cancer. 2019 Apr;66(4):e27556. doi: 10.1002/pbc.27556. Epub 2018 Nov 26. Review.

PMID:
30479064
7.

Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.

Alexander N, Marrano P, Thorner P, Naranjo A, Van Ryn C, Martinez D, Batra V, Zhang L, Irwin MS, Baruchel S.

J Pediatr Hematol Oncol. 2019 Apr;41(3):222-227. doi: 10.1097/MPH.0000000000001326.

PMID:
30334904
8.

Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.

Schechter T, Perez-Albuerne E, Lin TF, Irwin MS, Essa M, Desai AV, Frangoul H, Yanik G, Dupuis LL, Jacobsohn D, Kletzel M, Ranalli M, Soni S, Seif AE, Grupp S, Dvorak CC.

Bone Marrow Transplant. 2018 Sep 4. doi: 10.1038/s41409-018-0298-y. [Epub ahead of print]

PMID:
30181580
9.

Retrospective evaluation of a decision-support algorithm (MIPOGG) for genetic referrals for children with neuroblastic tumors.

Goudie C, Cullinan N, Villani A, Mathews N, van Engelen K, Malkin D, Irwin MS, Foulkes WD.

Pediatr Blood Cancer. 2018 Dec;65(12):e27390. doi: 10.1002/pbc.27390. Epub 2018 Aug 16.

PMID:
30117275
10.

Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma.

Fahy AS, Roberts A, Nasr A, Irwin MS, Gerstle JT.

J Pediatr Surg. 2018 Jul 6. pii: S0022-3468(18)30427-5. doi: 10.1016/j.jpedsurg.2018.06.031. [Epub ahead of print]

PMID:
30029845
11.

Autologous stem cell transplantation for refractory opsoclonus myoclonus ataxia syndrome.

Johnston DL, Murray S, Irwin MS, Doyle J, Schechter T.

Pediatr Blood Cancer. 2018 Aug;65(8):e27110. doi: 10.1002/pbc.27110. Epub 2018 Apr 25.

PMID:
29693780
12.

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR.

Pediatr Blood Cancer. 2018 Jul;65(7):e27023. doi: 10.1002/pbc.27023. Epub 2018 Mar 30.

13.

The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.

Alshareef A, Irwin MS, Gupta N, Zhang HF, Haque M, Findlay SD, Seong BKA, Lai J, Rayis M, Al-Dandan S, Lai R.

Oncotarget. 2018 Jan 12;9(12):10698-10713. doi: 10.18632/oncotarget.24216. eCollection 2018 Feb 13.

14.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

15.

Characteristics and management of ganglioneuroma and ganglioneuroblastoma-intermixed in children and adolescents.

Alexander N, Sullivan K, Shaikh F, Irwin MS.

Pediatr Blood Cancer. 2018 May;65(5):e26964. doi: 10.1002/pbc.26964. Epub 2018 Jan 25.

PMID:
29369484
16.

Comprehensive Analysis of Hypermutation in Human Cancer.

Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A.

Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19.

17.

Trends in post-mastectomy breast reconstruction types at a breast cancer tertiary referral centre before and after introduction of acellular dermal matrices.

Kankam HKN, Hourston GJM, Fopp LJ, Benson JR, Benyon SL, Irwin MS, Agrawal A, Forouhi P, Malata CM.

J Plast Reconstr Aesthet Surg. 2018 Jan;71(1):21-27. doi: 10.1016/j.bjps.2017.08.016. Epub 2017 Aug 31.

PMID:
28917935
18.

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG.

Cancer. 2017 Nov 1;123(21):4224-4235. doi: 10.1002/cncr.30873. Epub 2017 Jul 11.

19.

A direct comparison of porcine (Strattice™) and bovine (Surgimend™) acellular dermal matrices in implant-based immediate breast reconstruction.

Ball JF, Sheena Y, Tarek Saleh DM, Forouhi P, Benyon SL, Irwin MS, Malata CM.

J Plast Reconstr Aesthet Surg. 2017 Aug;70(8):1076-1082. doi: 10.1016/j.bjps.2017.05.015. Epub 2017 May 19.

PMID:
28624524
20.

Advancing Clinicopathologic Diagnosis of High-risk Neuroblastoma Using Computerized Image Analysis and Proteomic Profiling.

Niazi MKK, Chung JH, Heaton-Johnson KJ, Martinez D, Castellanos R, Irwin MS, Master SR, Pawel BR, Gurcan MN, Weiser DA.

Pediatr Dev Pathol. 2017 Sep-Oct;20(5):394-402. doi: 10.1177/1093526617698603. Epub 2017 Apr 18.

PMID:
28420318
21.

Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.

Allen CE, Laetsch TW, Mody R, Irwin MS, Lim MS, Adamson PC, Seibel NL, Parsons DW, Cho YJ, Janeway K; Pediatric MATCH Target and Agent Prioritization Committee.

J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djw274.

22.

Pediatric oncology enters an era of precision medicine.

Seibel NL, Janeway K, Allen CE, Chi SN, Cho YJ, Glade Bender JL, Kim A, Laetsch TW, Irwin MS, Takebe N, Tricoli JV, Parsons DW.

Curr Probl Cancer. 2017 May - Jun;41(3):194-200. doi: 10.1016/j.currproblcancer.2017.01.002. Epub 2017 Feb 1.

PMID:
28343740
23.

A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis.

Seong BK, Fathers KE, Hallett R, Yung CK, Stein LD, Mouaaz S, Kee L, Hawkins CE, Irwin MS, Kaplan DR.

Cancer Res. 2017 Feb 1;77(3):696-706. doi: 10.1158/0008-5472.CAN-16-1502. Epub 2016 Nov 29.

24.

Measuring primary tumor response in neuroblastoma: More than using a ruler.

Angelini P, Irwin MS.

Pediatr Blood Cancer. 2017 Jan;64(1):11-12. doi: 10.1002/pbc.26274. Epub 2016 Oct 20. No abstract available.

PMID:
27762062
25.

Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.

Hallett RM, Seong AB, Kaplan DR, Irwin MS.

Mol Oncol. 2016 Nov;10(9):1461-1472. doi: 10.1016/j.molonc.2016.07.012. Epub 2016 Aug 18.

26.

Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.

Waespe N, Van Den Akker M, Klaassen RJ, Lieberman L, Irwin MS, Ali SS, Abdelhaleem M, Zlateska B, Liebman M, Cada M, Schechter T, Dror Y.

Haematologica. 2016 Dec;101(12):1508-1515. Epub 2016 Aug 18.

27.

Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.

Marrano P, Irwin MS, Thorner PS.

Genes Chromosomes Cancer. 2017 Jan;56(1):28-41. doi: 10.1002/gcc.22398. Epub 2016 Aug 18.

PMID:
27465929
28.

Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database.

Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS.

Eur J Cancer. 2016 Sep;65:1-10. doi: 10.1016/j.ejca.2016.06.005. Epub 2016 Jul 17.

PMID:
27434878
29.

Surveillance imaging and radiation exposure in the detection of relapsed neuroblastoma.

Owens C, Li BK, Thomas KE, Irwin MS.

Pediatr Blood Cancer. 2016 Oct;63(10):1786-93. doi: 10.1002/pbc.26099. Epub 2016 Jun 15.

PMID:
27304424
30.

Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.

Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL.

Pediatr Blood Cancer. 2016 Jun;63(6):1019-23. doi: 10.1002/pbc.25934. Epub 2016 Feb 10.

31.

Neuroblastoma: paradigm for precision medicine.

Irwin MS, Park JR.

Pediatr Clin North Am. 2015 Feb;62(1):225-56. doi: 10.1016/j.pcl.2014.09.015. Review.

PMID:
25435121
32.

SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization.

Seong BK, Lau J, Adderley T, Kee L, Chaukos D, Pienkowska M, Malkin D, Thorner P, Irwin MS.

Oncogene. 2015 Jul;34(27):3582-92. doi: 10.1038/onc.2014.289. Epub 2014 Sep 15.

PMID:
25220418
33.

Spy'ing on differentiation in neuroblastoma.

Podkowa M, Irwin MS.

Oncotarget. 2014 Aug 15;5(15):5848-9.

34.

The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins.

Angelini P, Baruchel S, Marrano P, Irwin MS, Thorner PS.

Mod Pathol. 2015 Feb;28(2):166-76. doi: 10.1038/modpathol.2014.90. Epub 2014 Aug 1.

35.

Isolated late CNS relapse in a young adult 10 years after initial treatment for neuroblastoma.

Al-Faraj E, Millar BA, Irwin MS, Gupta A.

J Pediatr Hematol Oncol. 2015 Jan;37(1):75-7. doi: 10.1097/MPH.0000000000000163. No abstract available.

PMID:
24755834
36.

Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.

Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS.

J Clin Oncol. 2014 Apr 20;32(12):1228-35. doi: 10.1200/JCO.2013.53.6342. Epub 2014 Mar 24.

37.

Recurrent idiopathic painless shoulder weakness in a Navy F/A-18 aviator.

Walsh JC, Irwin MS, Weiss ZD.

Aviat Space Environ Med. 2013 Dec;84(12):1295-7.

PMID:
24459803
38.

Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma.

Wolter JK, Wolter NE, Blanch A, Partridge T, Cheng L, Morgenstern DA, Podkowa M, Kaplan DR, Irwin MS.

Oncotarget. 2014 Jan 15;5(1):161-72.

39.

Metachronous neuroblastoma in an infant with germline translocation resulting in partial trisomy 2p: a role for ALK?

Morgenstern DA, Soh SY, Stavropoulos DJ, Bowdin S, Baruchel S, Malkin D, Meyn MS, Irwin MS.

J Pediatr Hematol Oncol. 2014 Apr;36(3):e193-6. doi: 10.1097/MPH.0b013e3182a8f25d.

PMID:
24276038
40.

Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.

Morgenstern DA, Marzouki M, Bartels U, Irwin MS, Sholler GL, Gammon J, Yankanah R, Wu B, Samson Y, Baruchel S.

Pediatr Blood Cancer. 2014 Jan;61(1):128-33. doi: 10.1002/pbc.24656. Epub 2013 Aug 17.

PMID:
23956145
41.

Clinical outcomes in children with adrenal neuroblastoma undergoing open versus laparoscopic adrenalectomy.

Kelleher CM, Smithson L, Nguyen LL, Casadiego G, Nasr A, Irwin MS, Gerstle JT.

J Pediatr Surg. 2013 Aug;48(8):1727-32. doi: 10.1016/j.jpedsurg.2013.03.056.

PMID:
23932613
42.

Regulatory feedback loop between TP73 and TRIM32.

Gonzalez-Cano L, Hillje AL, Fuertes-Alvarez S, Marques MM, Blanch A, Ian RW, Irwin MS, Schwamborn JC, Marín MC.

Cell Death Dis. 2013 Jul 4;4:e704. doi: 10.1038/cddis.2013.224.

43.

Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity.

Blanch A, Robinson F, Watson IR, Cheng LS, Irwin MS.

PLoS One. 2013 Jun 14;8(6):e66436. doi: 10.1371/journal.pone.0066436. Print 2013.

44.

Diagnostic practices and disease surveillance in Canadian children with congenital central hypoventilation syndrome.

Amin R, Moraes TJ, Skitch A, Irwin MS, Meyn S, Witmans M.

Can Respir J. 2013 May-Jun;20(3):165-70.

45.

Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy.

Morgenstern DA, Baruchel S, Irwin MS.

J Pediatr Hematol Oncol. 2013 Jul;35(5):337-47. doi: 10.1097/MPH.0b013e318299d637. Review.

PMID:
23703550
46.

Late mortality after hematopoietic SCT for a childhood malignancy.

Schechter T, Pole JD, Darmawikarta D, Doyle J, Ali M, Egeler M, Gassas A, Irwin MS, Greenberg M, Nathan PC.

Bone Marrow Transplant. 2013 Oct;48(10):1291-5. doi: 10.1038/bmt.2013.64. Epub 2013 May 13.

PMID:
23665822
47.

Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.

Ashraf K, Shaikh F, Gibson P, Baruchel S, Irwin MS.

Pediatr Blood Cancer. 2013 Oct;60(10):1636-41. doi: 10.1002/pbc.24587. Epub 2013 May 3.

PMID:
23650219
48.

Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.

Bunda S, Kang MW, Sybingco SS, Weng J, Favre H, Shin DH, Irwin MS, Loh ML, Ohh M.

Cancer Res. 2013 Apr 15;73(8):2540-50. doi: 10.1158/0008-5472.CAN-12-3425. Epub 2013 Feb 11.

49.

Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma.

Wolter NE, Wolter JK, Enepekides DJ, Irwin MS.

J Otolaryngol Head Neck Surg. 2012 Oct;41(5):334-44.

PMID:
23092836
50.

Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1.

Wang Y, Roche O, Xu C, Moriyama EH, Heir P, Chung J, Roos FC, Chen Y, Finak G, Milosevic M, Wilson BC, Teh BT, Park M, Irwin MS, Ohh M.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):4892-7. doi: 10.1073/pnas.1112129109. Epub 2012 Mar 12.

Supplemental Content

Loading ...
Support Center